The term "oncogenic signaling" refers to the complicated molecular mechanisms that lead to the development and growth of cancer cells. Oncogenic signaling pathways are caused by various genetic mutations that interfere with normal cellular processes, leading to uncontrollable cell division, survival, and m…
The term "oncogenic signaling" refers to the complicated molecular mechanisms that lead to the development and growth of cancer cells. Oncogenic signaling pathways are caused by various genetic mutations that interfere with normal cellular processes, leading to uncontrollable cell division, survival, and migration. In recent years, significant advancements have been made in identifying and understanding the different oncogenic signaling pathways involved in cancer development. Some of the most well-known pathways include the PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and Wnt/?-catenin pathways, among others. Targeting oncogenic signaling pathways has become a promising approach in the treatment of cancer, as it helps to inhibit the growth and survival of cancer cells. Many pharmaceutical companies are now dedicating their resources to developing targeted therapies that can block one or more of these pathways and halt cancer progression. While much progress has been made in understanding oncogenic signaling, there is still much more to uncover. Ongoing research in this field aims to identify new targets and develop even more effective targeted therapies against cancer. As such, hematology and oncology researchers all over the world are working tirelessly to improve our understanding of oncogenic signaling, with the ultimate goal of finding a cure for cancer.
2 peer-reviewed articles, ranked by relevance. Each links to its DOI.
The 2 articles above have been cited 3 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
A sample of recent works citing this journal's research on Oncogenic Signaling, linking to each citing work.